Core Viewpoint - The competition in the weight loss drug market is intensifying, prompting multinational pharmaceutical companies to focus on weight loss drug assets in China [1]. Group 1: Company Developments - On February 25, after the opening of the Asia-Pacific stock market, the stock price of United Pharmaceuticals (3933.HK) surged, with an increase of over 7% in the afternoon following the announcement of mid-term clinical trial data for its new generation triple-target weight loss drug UBT251, which showed an average weight loss of 19.7% in the treatment group after 24 weeks compared to only 2% in the placebo group [2]. - Novo Nordisk entered into a licensing agreement with United Pharmaceuticals for UBT251 in March last year, with an upfront payment of $200 million and a potential total deal value of up to $2 billion [2]. - Novo Nordisk recently initiated a global trial involving approximately 330 overweight or obese patients using different doses of UBT251, with results expected in 2027, and plans to start a trial for type 2 diabetes patients [2]. Group 2: Industry Trends - On February 24, Chinese weight loss drug developer Senwa Biopharma announced a strategic partnership with Pfizer China, granting Pfizer exclusive commercialization rights for its core GLP-1 product, Enoglutide injection, in mainland China, with a total deal value of up to nearly $500 million [3]. - In December last year, Pfizer also reached a licensing agreement with a subsidiary of Fosun Pharma for a global exclusive right to an oral small molecule GLP-1 receptor agonist, with a deal value exceeding $2 billion [3]. - The global market for GLP-1 drugs is projected to reach $95 billion by 2030 and potentially expand to $120 billion by 2035, according to a report from Goldman Sachs [3].
减重药公司股价大涨，跨国巨头纷纷入局中国减重药资产